28.06.2018 • News

US SEC Charges S&P Analyst on Insider Trading

US SEC Charges S&P Analyst on Insider Trading (c) Don Nichols/Getty Images
US SEC Charges S&P Analyst on Insider Trading (c) Don Nichols/Getty Images

The US Securities and Exchange Commission (SEC) has charged an analyst with credit ratings agency Standard & Poor’s (S&P) and two of his friends with insider trading related to last year’s merger between paint firms Sherwin-Williams and Valspar.

Sherwin-Williams bought Valspar in a deal valued at $11.3 billion in June 2017.

In the lawsuit, filed in Manhattan, SEC alleges that Sebastian Pinto-Thomaz, an S&P analyst based in New York, learned of the proposed acquisition when Sherwin Williams consulted the agency about the deal’s potential affect on its credit rating.

The SEC said that Pinto-Thomaz tipped off his friends – Abell Oujaddou, a co-owner of an upmarket New York hair salon and Jeremy Millul, a New York jeweler – who bought Valspar shares and options before the merger was announced, then sold them afterward, making a profit of around $192,000 and $107,000 respectively.

In a parallel action, the US Attorney’s Office for the Southern District of New York has announced criminal charges against the three.

S&P told Reuters news agency that Pinto-Thomaz has been suspended and that it is cooperating with authorities.

 

 

From Catalogue to Collaboration

Enamine's Expert Insights Collection Is Free to Download
Enamine’s 35 Years of Advancing Drug Discovery

Enamine's Expert Insights Collection Is Free to Download

From catalogue to collaboration — explore 35 years of drug discovery breakthroughs, novel building blocks, and the science shaping tomorrow's medicines. Download your complimentary copy now.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read